Compare · EW vs FEED
EW vs FEED
Side-by-side comparison of Edwards Lifesciences Corporation (EW) and ENvue Medical Inc. (FEED): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EW and FEED operate in Industrial Specialties (Health Care), so they compete in similar markets.
- EW is the larger of the two at $49.36B, about 13650.0x FEED ($3.6M).
- EW has been more active in the news (6 items in the past 4 weeks vs 4 for FEED).
- EW has more recent analyst coverage (25 ratings vs 0 for FEED).
- Company
- Edwards Lifesciences Corporation
- ENvue Medical Inc.
- Price
- $85.70-2.46%
- $0.41-5.96%
- Market cap
- $49.36B
- $3.6M
- 1M return
- -3.25%
- -
- 1Y return
- +11.92%
- -
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 6
- 4
- Recent ratings
- 25
- 0
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Latest EW
- Edwards Lifesciences to Host Earnings Conference Call on July 23, 2026
- CVP, EMEACLA Bruls Annette covered exercise/tax liability with 109 shares, decreasing direct ownership by 0.53% to 20,628 units (SEC Form 4) (for withholding tax)
- CVP, Chief Financial Officer Mistras Theodora was granted 99,920 shares (SEC Form 4)
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $56,762 worth of shares (619 units at $91.70) as part of a pre-agreed trading plan (SEC Form 4)
- CVP, TAVR Lippis Daniel J. covered exercise/tax liability with 377 shares, decreasing direct ownership by 0.93% to 40,034 units (SEC Form 4) to cover taxes
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $56,577 worth of shares (619 units at $91.40) as part of a pre-agreed trading plan (SEC Form 4)
- Edwards’ Structural Heart Leadership Demonstrated Through Expanding Body of Scientific Evidence at New York Valves
- CEO Zovighian Bernard J sold $45,982 worth of shares (523 units at $87.92) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 11-K filed by Edwards Lifesciences Corporation
- SEC Form 11-K filed by Edwards Lifesciences Corporation
Latest FEED
- ENvue Medical Appoints Chairman of the Board and New Directors, Bringing Clinical, AI Governance and Capital Markets Expertise to Navigation Platform
- SEC Form PRE 14A filed by ENvue Medical Inc.
- SEC Form 8-K filed by ENvue Medical Inc.
- ENvue Medical Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
- No longer subject to section 1 Glibert Christian Michael sold $144,480 worth of shares (210,000 units at $0.69), closing all direct ownership in the company (SEC Form 4)
- ENvue Medical Launches AI Training Platform Establishing Artificial Intelligence Foundation for Robotic Feeding Tube Navigation
- ENvue Medical Expands into Burn Intensive Care Unit at Major Academic Health Network
- ENvue Medical Announces Publication of Landmark Independent Study Highlighting Significant Safety, Time-, and Cost-Saving Benefits of ENvue Navigation Platform in Multi-Hospital System
- SEC Form EFFECT filed by ENvue Medical Inc.
- SEC Form 424B3 filed by ENvue Medical Inc.